Sandoz acquires CIMERLI® business from Coherus further building biosimilar and ophthalmology leaders
资讯
2024-03-04
MEDIA RELEASE
CIMERLI®*, a ranibizumab biosimilar, is interchangeable with LUCENTIS®** (ranibizumab injection) for all approved indications
Dedicated retina sales and field reimbursement t...